Form 4: Fulgent Genetics COO Sells Shares for Tax Obligations

Fulgent Genetics President and COO Jian Xie sold 1,198 shares of common stock to cover tax liabilities from vested restricted stock units.

Summary

• Jian Xie, President and COO of Fulgent Genetics, Inc. (FLGT), reported a sale of common stock.
• The transaction involved the disposition of 1,198 shares of common stock on November 28, 2025.
• The shares were sold at a weighted-average price of $29.5695 per share, with individual transaction prices ranging from $29.45 to $29.67.
• The purpose of the sale was to satisfy tax withholding obligations arising from the vesting of restricted stock units (RSUs) granted on February 26, 2024.
• Following the reported transaction, Jian Xie directly beneficially owns 337,889 shares of common stock.
• Additionally, 220,816 shares are indirectly beneficially owned through The Hsieh Family Dynasty Trust, dated January 27, 2010, where Mr. Xie serves on the investment committee.

Sentiment

Score: 5

Explanation: The filing reports a routine sale of shares by an executive to cover tax withholding obligations upon the vesting of restricted stock units. This is a common and often mandatory event for executives and is generally considered a neutral event, not indicative of positive or negative sentiment towards the company's performance or future.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing details a routine insider transaction, specifically a sale of shares by an executive to cover tax obligations associated with vested equity compensation. Such transactions are common across industries for executives receiving restricted stock units or other forms of equity-based pay, and they typically do not reflect a change in the executive's confidence in the company's long-term prospects or its operational performance.

Related Party Transactions

• Securities held by The Hsieh Family Dynasty Trust, dated January 27, 2010, where Mr. Xie serves on the investment committee. Mr. Xie disclaims beneficial interest except for any pecuniary interest.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, tax-related sale of a relatively small number of shares by an executive, which is unlikely to significantly affect the company's stock price or long-term value.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

This Form 4 reports a routine sale of shares by an executive to cover tax obligations upon the vesting of restricted stock units. Such transactions are common and generally do not indicate a change in the company's fundamentals or the executive's long-term outlook. Therefore, it does not provide a basis for a change in investment recommendation.

Keywords

Fulgent Genetics, FLGT, Insider Transaction, Form 4, Stock Sale, Executive Compensation, Restricted Stock Units, Tax Withholding